Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (251-260 of 390) with videos related to

Pageof 39
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2024
CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective studyMastura Monif, Richard P Sequeira, Andrea Muscat, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
Human Molecular Genetics|July 19, 2015
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosisBen J Gu, Judith Field, Sébastien Dutertre, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis and Related Disorders|December 20, 2025
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-studyHelmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Pageof 39

Showing results (251-260 of 390) with videos related to

Sort By:
Pageof 39
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Clinical Immunology (Orlando, Fla.)|July 4, 2024
CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective studyMastura Monif, Richard P Sequeira, Andrea Muscat, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
Human Molecular Genetics|July 19, 2015
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosisBen J Gu, Judith Field, Sébastien Dutertre, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis and Related Disorders|December 20, 2025
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-studyHelmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Pageof 39